Mouse TRPV2(Transient Receptor Potential Cation Channel Subfamily V, Member 2) ELISA Kit

Description:

• Related to: Filoviruses
• Applications: ELISA

Description:

• Related to: Filoviruses
• Applications: ELISA

Description: The Mouse ; Testis is available in Europe and for worldwide shipping via Gentaur.

Description: The Mouse ; Thymocyte is available in Europe and for worldwide shipping via Gentaur.

Description:

• Related to: Staphylococcus
• Applications: ELISA

Description: Mouse monoclonal Mouse anti Human IgE antibody

Description: Mouse monoclonal Mouse anti Human IgE antibody

Description: Mouse monoclonal Mouse anti Human IgE antibody

Description:

• Related to: Staphylococcus
• Applications: ELISA, WB

Description:

• Related to: Staphylococcus
• Applications: ELISA, WB

Description:

• Related to: Staphylococcus
• Applications: ELISA, WB

Description:

• Related to: Staphylococcus
• Applications: ELISA, WB

Description:

• Related to: Filoviruses
• Applications: ELISA, WB

Description:

• Related to: Filoviruses
• Applications: ELISA, WB

Description:

• Related to: Filoviruses
• Applications: ELISA, WB

Description:

• Related to: Filoviruses
• Applications: ELISA

Description:

• Related to: Filoviruses
• Applications: ELISA, WB

Description:

• Related to: Staphylococcus
• Applications: ELISA

Description:

• Related to: Filoviruses
• Applications: ELISA, WB

Description:

• Related to: Filoviruses
• Applications: ELISA, WB

Description:

• Related to: Filoviruses
• Applications: ELISA, WB

Description:

• Related to: Filoviruses
• Applications: ELISA

Description:

• Related to: Filoviruses
• Applications: ELISA, WB

Description:

• Related to: Filoviruses
• Applications: ELISA, WB

Description: This is Mouse monoclonal FITC conjugated antibody against Epstein-Barr virus gp 250/350 for WB, ELISA.

Description: ELISA based test for quantitative detection of CA50 (Cancer antigen)

Description: ELISA based test for quantitative detection of ?-HCG (Human chorionic gonadotropin)

Description:

• Related to: Other Viruses
• Applications: ELISA, WB

Description: Please contact Gentaur in order to receive the datasheet of the product.

Description: Minimum order quantity: 1 unit of 1SET

Description: HIV-1 reverse transcriptase recombinant antigen.

Description: HIV-1 reverse transcriptase recombinant antigen.

Description: The HIV-1Reverse transcriptase is available in Europe and for worldwide shipping via Gentaur.

Description: The HIV-1Reverse transcriptase is available in Europe and for worldwide shipping via Gentaur.

Description: Minimum order quantity: 1 unit of 1mg

Description: Minimum order quantity: 1 unit of 1mg

Description: Minimum order quantity: 1 unit of 1mg

Description: Minimum order quantity: 1 unit of 1mg

Description: Minimum order quantity: 1 unit of 1mg

Description: Minimum order quantity: 1 unit of 1mg

Description: Minimum order quantity: 1 unit of 1mg

Description: Minimum order quantity: 1 unit of 1SET

Description: Please contact Gentaur in order to receive the datasheet of the product.

Description: Please contact Gentaur in order to receive the datasheet of the product.

Description: Mouse monoclonal Dengue NS1 antibody (Subtype 2/3)

Description: Mouse monoclonal Dengue NS1 antibody (Subtype 2/4)

Description: Angiotensin-Converting Enzyme 2 (ACE-2) is an integral membrane protein and a zinc metalloprotease of the ACE family which includes somatic and germinal ACE. ACE-2 cleaves angiotensins I and II as a carboxypeptidase and converts angiotensin I to angiotensin 1-9, and angiotensin II to angiotensin 1-7. ACE-2 is also able to hydrolyze apelin-13 and dynorphin-13 with high efficiency. ACE-2 can be highly expressed in testis, kidney, heart, colon, small intestine and ovary at moderate levels. ACE2 is not inhibited by the classical ACE inhibitors, captopril and lisinopril and may play an important role in regulating the heart function.

Description: Please contact Gentaur in order to receive the datasheet of the product.

Description: HSV-2 gD recombinant antigen a.a. 266-394.

Description: HSV-2 gD recombinant antigen a.a. 266-394.

Description: HSV-2 gD recombinant antigen a.a. 525-578.

Description: HSV-2 gD recombinant antigen a.a. 525-578.

Description: HIV-2 gp32 recombinant antigen. .

Description: HIV-2 gp32 recombinant antigen. .

Description: Minimum order quantity: 1 unit of 100MG

Description: HIV -2 env gp36 recombinant antigen a.a 390 to a.a 702 of the HIV-2 env region 34 kDa

Description: HIV -2 env gp36 recombinant antigen a.a 390 to a.a 702 of the HIV-2 env region 34 kDa

Description: HIV -2 env gp36 recombinant antigen. a.a 390 to a.a 702.

Description: HIV -2 env gp36 recombinant antigen. a.a 390 to a.a 702.

Description: HCV core 2-119aa recombinant antigen. Genotypes available: 1a, 1b, 2a, 2b, 3a, 3b, 3/10, 4, 5, 6a

Description: HCV core 2-119aa recombinant antigen. Genotypes available: 1a, 1b, 2a, 2b, 3a, 3b, 3/10, 4, 5, 6a

Description: HIV 1, 2 envelope recombinant antigen. HIV-1 envelope conjugated to HIV-2 envelope peptide.

Description: HIV 1, 2 envelope recombinant antigen. HIV-1 envelope conjugated to HIV-2 envelope peptide.

Description: Minimum order quantity: 1 unit of 10MG

Description: Recombinant human interleukin-2 is a sterile protein product for injection. rHuIL-2 is produced by recombinant DNA technology using Yeast. It is a highly purified protein containing 133 amino acids, with cysteine mutated to alanine at 125 amino acid position, and has a molecular weight of approximately 15.4kD, non-glycosylated.

Description: Mouse monoclonal alpha 2 Antiplasmin antibody

Description: Mouse monoclonal alpha 2 Antiplasmin antibody

Description: Mouse monoclonal beta 2 Microglobulin antibody

Description: Mouse monoclonal beta 2 Microglobulin antibody

Description: Mouse monoclonal Dengue Type 2 antibody

Description: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is an enveloped, single-stranded, positive-sense RNA virus that belongs to the Coronaviridae family 1. The SARS-CoV-2 genome, which shares 79.6% identity with SARS-CoV, encodes four essential structural proteins: the spike (S), envelope (E), membrane (M), and nucleocapsid protein (N) 2. The S protein is a transmembrane, homotrimeric, class I fusion glycoprotein that mediates viral attachment, fusion, and entry into host cells 3. Each ~180 kDa monomer contains two functional subunits, S1 (~700 a.a) and S2 (~600 a.a), that mediate viral attachment and membrane fusion, respectively. S1 contains two major domains, the N-terminal (NTD) and C-terminal domains (CTD). The CTD contains the receptor-binding domain (RBD), which binds to the angiotensin-converting enzyme 2 (ACE2) receptor on host cells 3-5. Although both SARS-CoV and SARS-CoV-2 bind the ACE2 receptor, the RBDs only share ~73% amino acid identity, and the SARS-CoV-2 RBD binds with a higher affinity compared to SARS-CoV 3, 6. The RBD is dynamic and undergoes hinge-like conformational changes, referred to as the “down” or “up” conformations, which hide or expose the receptor-binding motifs, respectively 7. Following receptor binding, S1 destabilizes, and TMPRSS2 cleaves S2, which undergoes a pre- to post-fusion conformation transition, allowing for membrane fusion 8, 9. _x000D__x000D__x000D_Polyclonal RBD-specific antibodies can block ACE2 binding 10, 11, and anti-RBD neutralizing antibodies are present in the sera of convalescent COVID19 patients 12, identifying the RBD as an attractive candidate for vaccines and therapeutics. In addition, the RBD is poorly conserved, making it a promising antigen for diagnostic tests 13 14. Serologic tests for the RBD are highly sensitive and specific for detecting SARS-CoV-2 antibodies in COVID19 patients 13 15. Furthermore, the levels of anti-RBD antibodies correlated with SARS-CoV-2 neutralizing antibodies, suggesting the RBD could be used to predict an individual's risk of disease 13._x000D_

Description: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is an enveloped, single-stranded, positive-sense RNA virus that belongs to the Coronaviridae family 1. The SARS-CoV-2 genome, which shares 79.6% identity with SARS-CoV, encodes four essential structural proteins: the spike (S), envelope (E), membrane (M), and nucleocapsid protein (N) 2. The S protein is a transmembrane, homotrimeric, class I fusion glycoprotein that mediates viral attachment, fusion, and entry into host cells 3. Each ~180 kDa monomer contains two functional subunits, S1 (~700 a.a) and S2 (~600 a.a), that mediate viral attachment and membrane fusion, respectively. S1 contains two major domains, the N-terminal (NTD) and C-terminal domains (CTD). In both SARS-CoV and SARS-CoV-2, the CTD contains the receptor-binding domain (RBD), which binds to the angiotensin-converting enzyme 2 (ACE2) receptor on host cells3-5. The NTD of SARS-CoV-2 does not bind to ACE26, and the function of NTD in SARS-CoV-2 infection is not well understood. In other CoVs, the NTD may promote attachment by binding to sugar moieties7 and might play a role in the conformational change of S2 required for membrane fusion8. While most neutralizing antibodies target the RBD domain and block receptor binding, potent neutralizing antibodies targeting NTD were isolated from convalescent COVID19 patients9, identifying the NTD as an attractive candidate for vaccines and therapeutics. In addition, the NTD is a promising antigen for diagnostic tests, as there is only 53.5% homology between the NTD of SARS-CoV-2 and SARS-CoV10.

Description: LOCUS: QHD43422 121aa linear VRL 18-MAR-2020

Description: LOCUS: QHD43417 275aa linear VRL 18-MAR-2020

Description: SARS-CoV-2 (COVID-19) Envelope Recombinant Protein

Description: HIV 2 gp36 envelope antigen. Synthetic HIV-2 Peptide containing the HIV-2 specific sequence of gp36.

Description: HIV 2 gp36 envelope antigen. Synthetic HIV-2 Peptide containing the HIV-2 specific sequence of gp36.

Description: anti-HIV-2 gp36 IgG1 (monoclonal) Produced against a recombinant protein.

Description: anti-HIV-2 gp36 IgG1 (monoclonal) Produced against a recombinant protein.

Description: SARS-CoV-2 (COVID-19) Nucleocapsid Recombinant Protein

Description: The spike protein (S) of coronavirus (CoV) attaches the virus to its cellular receptor, angiotensin-converting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses as well as protective immunity.

Description: The spike protein (S) of coronavirus (CoV) attaches the virus to its cellular receptor, angiotensin-converting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses as well as protective immunity.

Description: The spike protein (S) of coronavirus (CoV) attaches the virus to its cellular receptor, angiotensin-converting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses as well as protective immunity.

Description: SARS-CoV-2 (COVID-19) Spike S1 Recombinant Protein

Description: The spike protein (S) of coronavirus (CoV) attaches the virus to its cellular receptor, angiotensin-converting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses as well as protective immunity.

Description: SARS-CoV-2 (COVID-19) Spike RBD Recombinant Protein

Description: SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. SARS CoV-2 spike protein is composed of S1 domain and S2 domain. S1 contains a receptor-binding domain (RBD) that can specifically bind to angiotensin-converting enzyme 2 (ACE2), the receptor on the target cells. SARS-CoV-2 spike protein (RBD) has the potential value for the diagnosis of the virus.

Description: SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. SARS CoV-2 spike protein is composed of S1 domain and S2 domain. S1 contains a receptor-binding domain (RBD) that can specifically bind to angiotensin-converting enzyme 2 (ACE2), the receptor on the target cells. SARS-CoV-2 spike protein (RBD) has the potential value for the diagnosis of the virus.

Description: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is an enveloped, single-stranded, positive-sense RNA virus that belongs to the Coronaviridae family 1. The SARS-CoV-2 genome, which shares 79.6% identity with SARS-CoV, encodes four essential structural proteins: the spike (S), envelope (E), membrane (M), and nucleocapsid protein (N) 2. The S protein is a transmembrane, homotrimeric, class I fusion glycoprotein that mediates viral attachment, fusion, and entry into host cells 3. Each ~180 kDa monomer contains two functional subunits, S1 (~700 a.a) and S2 (~600 a.a), that mediate viral attachment and membrane fusion, respectively. S1 contains two major domains, the N-terminal (NTD) and C-terminal domains (CTD). In both SARS-CoV and SARS-CoV-2, the CTD contains the receptor-binding domain (RBD), which binds to the angiotensin-converting enzyme 2 (ACE2) receptor on host cells 3-5. The NTD of SARS-CoV-2 does not bind to ACE2 6, and the function of NTD in SARS-CoV-2 infection is not well understood. In other CoVs, the NTD may promote attachment by binding to sugar moieties 7 and might play a role in the conformational change of S2 required for membrane fusion 8. While most neutralizing antibodies target the RBD domain and block receptor binding, potent neutralizing antibodies targeting NTD were isolated from convalescent COVID19 patients 9, identifying the NTD as an attractive candidate for vaccines and therapeutics. In addition, the NTD is a promising antigen for diagnostic tests, as there is only 53.5% homology between the NTD of SARS-CoV-2 and SARS-CoV 10.

Description: Recombinant human interleukin-2 is a sterile protein product for injection. rHuIL-2 is produced by recombinant DNA technology using Yeast. It is a highly purified protein containing 133 amino acids, with cysteine mutated to alanine at 125 amino acid position, and has a molecular weight of approximately 15.4kD, non-glycosylated.

Description: SARS-CoV-2 (COVID-19) Spike S2 ECD Recombinant Protein

Description: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is an enveloped, single-stranded, positive-sense RNA virus that belongs to the Coronaviridae family 1. The SARS-CoV-2 genome, which shares 79.6% identity with SARS-CoV, encodes four essential structural proteins: the spike (S), envelope (E), membrane (M), and nucleocapsid protein (N) 2. The S protein is a transmembrane, homotrimeric, class I fusion glycoprotein that mediates viral attachment, fusion, and entry into host cells 3. Each ~180 kDa monomer contains two functional subunits, S1 (~700 a.a) and S2 (~600 a.a), that mediate viral attachment and membrane fusion, respectively. S1 contains two major domains, the N-terminal (NTD) and C-terminal domains (CTD). The CTD contains the receptor-binding domain (RBD), which binds to the angiotensin-converting enzyme 2 (ACE2) receptor on host cells 3-5. Although both SARS-CoV and SARS-CoV-2 bind the ACE2 receptor, the RBDs only share ~73% amino acid identity, and the SARS-CoV-2 RBD binds with a higher affinity compared to SARS-CoV 3, 6. The RBD is dynamic and undergoes hinge-like conformational changes, referred to as the “down” or “up” conformations, which hide or expose the receptor-binding motifs, respectively 7. Following receptor binding, S1 destabilizes, and TMPRSS2 cleaves S2, which undergoes a pre- to post-fusion conformation transition, allowing for membrane fusion 8, 9. The S protein has been the main focus of therapeutic and vaccine design as it is highly immunogenic. Both neutralizing antibodies 10,11 and memory T cells 12,13 targeting the S protein are present in the sera of convalescent COVID-19 patients.

Description: The spike protein (S) of coronavirus (CoV) attaches the virus to its cellular receptor, angiotensin-converting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses as well as protective immunity.

Description: The spike protein (S) of coronavirus (CoV) attaches the virus to its cellular receptor, angiotensin-converting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses as well as protective immunity.